Preclinical pharmacokinetics of a novel HIV-1 attachment inhibitor BMS-378806 and prediction of its human pharmacokinetics-Reference-Cited by-同舟云学术

Preclinical pharmacokinetics of a novel HIV-1 attachment inhibitor BMS-378806 and prediction of its human pharmacokinetics

Published:2005 Issue:9 Volume:26 Page:387-402
ISSN:0142-2782
Container-title:Biopharmaceutics & Drug Disposition
language:en
Short-container-title:Biopharm. Drug Dispos.

Author:

Yang Zheng,Zadjura Lisa,D'Arienzo Celia,Marino Anthony,Santone Kenneth,Klunk Lewis,Greene Douglas,Lin Pin-Fang,Colonno Richard,Wang Tao,Meanwell Nicholas,Hansel Steven

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science,Pharmacology,General Medicine

Reference33 articles.

1. HIV and AIDS: 20 years of science

2. Twenty years of therapy for HIV-1 infection

3. A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding

4. Discovery of 4-Benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): A Novel HIV-1 Attachment Inhibitor That Interferes with CD4-gp120 Interactions

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Indol-3-ylglyoxylamide as Privileged Scaffold in Medicinal Chemistry;Pharmaceuticals;2023-07-12

2. Safety pharmacology;A Pharmacology Primer;2022

3. The Alpha Keto Amide Moiety as a Privileged Motif in Medicinal Chemistry: Current Insights and Emerging Opportunities;Journal of Medicinal Chemistry;2021-03-25

4. In vitro Identification of Spinosin Metabolites in Human Liver Microsomes Using a Simple and Sensitive UHPLC-Q-TOF-MS/MS Method;Current Pharmaceutical Analysis;2019-12-20

5. Safety Pharmacology;A Pharmacology Primer;2019